Interleukin-10 but not transforming growth factor-β1 gene expression is up-regulated by vitamin D treatment in multiple sclerosis patients

J Neurol Sci. 2015 Mar 15;350(1-2):18-23. doi: 10.1016/j.jns.2015.01.030. Epub 2015 Jan 28.

Abstract

Multiple sclerosis (MS) is an inflammatory and autoimmune disease. Variety of different genetics and environmental factors are involved in MS pathology. The epidemiological studies demonstrated that vitamin D has immune and immunomodulating effects on MS disease. Therefore, this study aims to evaluate the effect of vitamin D treatment on the expression of interleukin-10 (IL-10) and transforming growth factor-β1 (TGF-β1) genes in MS patients. We found that, the expression level of IL-10 gene in treated patients was up-regulated 3.84 times more than before treatment, but the expression level of TGF-β1 was not affected by vitamin D treatment. Also, a significant relationship was observed between vitamin D level and EDSS in MS patients. Our results indicated that the increased level of serum vitamin D and IL-10 gene expression may be associated with the reduction of EDSS scores in MS patients.

Keywords: EDSS; IL-10; Multiple sclerosis; TGF-β1; Vitamin D; qRT-PCR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Humans
  • Injections, Intramuscular
  • Interleukin-10 / biosynthesis*
  • Male
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / drug therapy*
  • Transforming Growth Factor beta1 / biosynthesis*
  • Treatment Outcome
  • Up-Regulation / drug effects
  • Up-Regulation / physiology*
  • Vitamin D / administration & dosage*
  • Vitamin D / blood
  • Young Adult

Substances

  • IL10 protein, human
  • Transforming Growth Factor beta1
  • Interleukin-10
  • Vitamin D